| HOME >> BIOLOGY >> TECHNOLOGY |
TOTAL CURRENT ASSETS 1,709,392
PROPERTY AND EQUIPMENT, NET OF ACCUMULATED DEPRECIATION 19,324,273
DEFERRED INTEREST 9,011,856
TOTAL ASSETS $30,045,521
CURRENT LIABILITIES:
Short-term borrowings $266,042
Accounts payable 638,781
Loan payable - other 573,550
Due to stockholders 685,798
Accrued expenses and taxes payable 2,286,924
Current portion of long-term debt 6,983,473
TOTAL CURRENT LIABILITIES 11,434,568
LONG-TERM DEBT 4,389,699
CONVERTIBLE DEBENTURES 2,347,000
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value,
100,000,000 shares authorized
41,595,507 shares issued and outstanding 40,595
Preferred stock, $0.001 par value,
300,000 shares authorized
277,018 shares issued and outstanding 277
Additional paid-in capital 19,470,686
Deferred stock compensation (255,277)
Accumulated deficit (7,807,723)
Other comprehensive income 425,696
TOTAL STOCKHOLDERS' EQUITY 11,874,254
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $30,045,521
CONSOLIDATED STATEMENTS OF OPERATIONS
'/>"/>
| SOURCE China Aoxing Pharmaceutical Company, Inc. Copyright©2007 PR Newswire. All rights reserved |